U.S. markets open in 7 hours 36 minutes

Invesco Global Listed Private Equity ETF (PSP)

NYSEArca - NYSEArca Delayed Price. Currency in USD
Add to watchlist
15.95-0.09 (-0.56%)
At close: 3:59PM EDT
Sign in to post a message.
  • W
    Wilberto
    🚀🚀🚀🚀💸💵💰

    Inovio is getting less investor attention because its competition is winning production deals first. For example, Novavax and AstraZeneca (NYSE:AZN) signed a deal to supply vaccines to Japan. These deals are more like a memorandum of understanding. Neither AstraZeneca nor Novavax have an approved vaccine.
    Similarly, Moderna (NASDAQ:MRNA), whose shares peaked at $95.21 only to close recently at $74, is signing similar deals. The Swiss government signed an agreement with Moderna. Switzerland secured early access by getting 4.5 million doses of the vaccine. At two doses per patient, it would protect 2.25 million people.
    On Aug. 11, Russia announced approval of the first Covid-19 vaccine, although the drug still hasn’t completed clinical trials.
    Investors are understandably cautious with Inovio’s potential vaccine sales at this time. The company did not secure contract manufacturing for the vaccine. It sued its manufacturing partner VGXI, accusing it of withholding technical knowledge.
    Unlike with Moderna and Novavax, which secured massive funding from government, Inovio received “only” $71 million from the Department of Defense. The DoD will support the large-scale manufacturer of CELLECTRA #PSP. This is a smart device used to deliver INO-4800.
    By comparison, Moderna received another $472 million for vaccine development from the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA). Novavax received $1.6 billion funding from the government from Operation Warp Speed.
    The average analyst price target on Inovio is $23.20 (per Stockrover). Analysts estimate that sales will grow by 1355%. Conversely, the fair value (based on enterprise value to sales) is $29.17.
    The Covid-19 vaccine race is heating up. The winners today earned the most funding and have the advantage, for now. Things may change quickly. Moderna and Novavax may not have as effective a vaccine as Inovio. Investors betting on this will get rewarded by investing in INO shares instead.
    Clinical results from all vaccine developers will give investors more clarity in the coming weeks. Any good news will drive the value of INO stock and its competitors higher. Just as easily possible is that any bad news would hurt their valuations.
    Bullish
  • W
    Wilberto
    Speculators may have piled on their bet elsewhere. For example, Novavax (NASDAQ:NVAX) traded as high as $189.40 after posting its early-stage Covid-19 vaccine data.
    Are markets making a mistake after forgetting about Inovio’s positive preclinical results posted on July 30?
    INO Stock Drops After Vaccine Data
    Inovio announced that its DNA vaccine to Covid-19, INO-4800, protected non-human primates from the virus. The vaccine showed durable antibody and T-cell responses. Its non-human subjects, rhesus macaques, is a species of monkey that should have some similarities with humans. The company challenged the subjects with live virus 13 weeks after the last vaccination. It observed a T- and B-cell immune response.
    • 7 Innovative Stocks to Buy That Are Pushing the Envelope
    Scientists saw that viral loads fell in both the lower lungs and nasal passages. The subjects received two doses at 1 mg four weeks apart. After a single vaccination, the animals developed an antibody that was detectable in their bloodstreams.
    By challenging animals weeks after vaccination instead of at their peak immune response, Inovio is mimicking a real-world scenario with how people might get exposed. The results suggest that INO-4800 is a potential vaccine solution that the world needs.
    Competition
    Inovio is getting less investor attention because its competition is winning production deals first. For example, Novavax and AstraZeneca (NYSE:AZN) signed a deal to supply vaccines to Japan. These deals are more like a memorandum of understanding. Neither AstraZeneca nor Novavax have an approved vaccine.
    Similarly, Moderna (NASDAQ:MRNA), whose shares peaked at $95.21 only to close recently at $74, is signing similar deals. The Swiss government signed an agreement with Moderna. Switzerland secured early access by getting 4.5 million doses of the vaccine. At two doses per patient, it would protect 2.25 million people.
    On Aug. 11, Russia announced approval of the first Covid-19 vaccine, although the drug still hasn’t completed clinical trials.
    Investors are understandably cautious with Inovio’s potential vaccine sales at this time. The company did not secure contract manufacturing for the vaccine. It sued its manufacturing partner VGXI, accusing it of withholding technical knowledge.
    Unlike with Moderna and Novavax, which secured massive funding from government, Inovio received “only” $71 million from the Department of Defense. The DoD will support the large-scale manufacturer of CELLECTRA #PSP. This is a smart device used to deliver INO-4800.
    By comparison, Moderna received another $472 million for vaccine development from the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA). Novavax received $1.6 billion funding from the government from Operation Warp Speed.
    Fair Value
    The average analyst price target on Inovio is $23.20 (per Stockrover). Analysts estimate that sales will grow by 1355%. Conversely, the fair value (based on enterprise value to sales) is $29.17. This gives the stock a margin of safety of 45%.

    <img alt="INO Stock" class="alignright wp-image-1684256 size-full" height="692" src="https://investorplace-com.cdn.ampproject.org/i/s/investorplace.com/wp-content/uploads/2020/08/ip-ino.jpg" width="956">

    Source: Stockrover
    The chart above suggests that the stock will find support at its 50-day moving average at $20. If bears continue to sell, the sharp drop in the moving average convergence divergence signals more downside ahead. Inovio could trade at below $15 near its 150-day moving average.

    View our fishing products
    We sell baits, lures, flies, fish finders, rods, and much
    more.
    CE Showroom, Inc.

    Open

    Ads by
    Stop seeing this ad
    Why this ad? 

    Ads by
    Stop seeing this ad
    Why this ad? 
    Ad covered content
    Not interested in this ad
    Seen this ad multiple times
    Ad was inappropriate

    We'll try not to show that ad again
    We'll try not to show that ad again

    Ad closed by
    Ad closed by

    Your Takeaway
    The Covid-19 vaccine race is heating up. The winners today earned the most funding and have the advantage, for now. Things may change quickly. Moderna and Novavax may not have as effective a vaccine as Inovio. Investors betting on this will get rewarded by investing in INO shares instead.
    Clinical results from all vaccine developers will give investors more clarity in the coming weeks. Any good news will drive the value of INO stock and its competitors higher. Just as easily possible is that any bad news would hurt their valuations.
    Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities.
    Bullish
  • A
    Anonymous
    Looking for some of the best stock picks on the market? You need to go to awesome-STOCKS right now then! .
  • A
    Anonymous
    Forget buy and hold…Make real returns being a “trader” Check out THELIONSTCOKALERTS (Gooogle) .
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week low at $10.11
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week low at $10.31
  • Y
    Yahoo Finance Insights
    PSP reached a new 52 Week Low at $11.58
  • Y
    Yahoo Finance Insights
    PSP reached a new 52 Week Low at $11.10
  • A
    Anonymous
    Doing research on new stocks is getting so hard. That’s why I joined up with this free service that sends one solid stock pick every single week. So far the picks have been great. Just go to awesomeS-TOCKS to learn more. .
  • A
    Anonymous
    Home - Trade Alerts
    tradeanalysis.zohosites.com
  • A
    Anonymous
    Who says PSP isn't poised for potentially massive upward movement? google awesome-STOCKS - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
  • A
    Anonymous
    Received an alert this am about $PSP from http://dd.report/?s=PSP, you may want to take a look. Day trading investing. "hhse"
    DD Report | Due Diligence Reports
    dd.report
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week high at 14.08
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week low at 10.09
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week low at 10.24
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week low at 10.24
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week low at 10.09
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week low at 9.39
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week low at 6.69
  • Y
    Yahoo Finance Insights
    PSP reached a 52 Week low at 8.44